Abbvie is investing heavily in Parkinsonian diseases, and received approval for a short-acting drug (90 minutes?) and cumbersome (patient wears a pump and drug is "infused"): https://www.parkinson.org/blog/science-news/produodopa Inferior to ATH434 IMO in that it has a 24% "drop-out": rate, due to adverse reaction to infusion site, and nonly targets symptoms, not underlying cause of motor function issues.
"Onapgo (Apomorphine Hydrochloride):Approved in February 2025.A continuous under-the-skin infusion of apomorphine.Helps control motor symptoms like tremors.The first infusion-based apomorphine therapy approved in the US for Parkinson's.Intended for individuals with progressing Parkinson's disease experiencing significant 'off' times or motor fluctuations.
Vyalev (Foscarbidopa and Foslevodopa): Approved in October 2024.A subcutaneous 24-hour continuous infusion of levodopa-based therapy.Intended for adults with advanced Parkinson's disease.Shown to improve "on" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa.Allows for personalized dosing based on individual needs."
Abbvie (again IMO) must be watching ATHE closely.
ATH Price at posting:
0.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)